July 20, 2022 – Singapore-based biotech start-up, Tetris Therapeutics Pte. Ltd. announced today that it has changed its name to Axcynsis Therapeutics Pte. Ltd.. The new name will better reflect the company’s core business and platform technology – AXC (Antibody-X Conjugate) Synthesis.
“Antibody Drug Conjugates (ADCs) are a class of anticancer agents designed by conjugating cytotoxic drugs to monoclonal antibodies.” said Dr. Zou Bin, founder and CEO of Axcynsis Therapeutics. “In fact, this concept can be extended beyond cytotoxic drugs. Hence we are developing our platform technologies to synthesize Antibody-X Conjugates, where “X” could be any molecules that disrupt the abnormal cells.”
Axcynsis Therapeutics will continue to strengthen the company’s pipeline and provide new treatment options to address unmet medical needs.
About Axcynsis Therapeutics Pte. Ltd.
Axcynsis Therapeutics Pte. Ltd. is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprietary technologies, we are developing a robust pipeline of AXC candidates with the potential to address unmet medical needs for new treatment options.
For all media queries, please contact:
Wong Yun Xuan